RMD News: Health Care Roundup: Market Talk - 30th Oct 2023, 10:26pm

[annb0t]

0540 GMT – Hangzhou Tigermed’s nine-month topline results for don’t look upbeat to Nomura analyst Jialin Zhang, who lowers projections for the pharma services company. Topline growth decelerated over the nine months, while margins narrowed, Nomura says. Nomura lowers A share target 9.3% to CNY75.72 but keeps a buy rating.

Continue reading

>>> Read more: Health Care Roundup: Market Talk